Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.

This is a phase I, multi-center, open-label, dose-escalation study to evaluate the safety, tolerability, pharmacokinetics and clinical activity of LP-168 in subjects with relapsed or refractory B-cell malignancies. LP-168 is a small molecule inhibitor.

Trial Details

NCT ID
NCT04775745
Phase
PHASE1
Sponsor
Newave Pharmaceutical Inc
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • LP-168
Locations (sample)
  • Durham, North Carolina, United States|35.99403,-78.89862
  • Cincinnati, Ohio, United States|39.12711,-84.51439
  • Columbus, Ohio, United States|39.96118,-82.99879
  • Salt Lake City, Utah, United States|40.76078,-111.89105

Key Eligibility Criteria

  • A subject will be eligible for study participation if he/she meets the following criteria:
  • Subjects are eligible with B-cell malignancies, WM, FL, MCL, MZL, DLBCL, HCL, CLL, SLL, based upon 2016 updated WHO classification. Those subjects …
  • Low-grade B-cell lymphomas as follicular Grade 1, 2, or 3A, marginal zone or small lymphocytic lymphoma.
  • Subject must have adequate coagulation, renal, and hepatic function, per local laboratory reference ranges at Screening as follows:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →